Biosimilar to rituximab; a chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them primarily via antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity, with additional direct apoptotic signaling, thereby reducing B‑cell–mediated immune responses.